The spring is a busy time for health regulators in China, and within two weeks they have announced several significant policy shifts that will generate a profound impact on the pharma industry.
China First: Beijing's Bolstering Of Generics Rekindles IPR Fears
The message is unmistakably clear: new policies are putting China first to make drugs more accessible and affordable, including widely prescribed products for cancer. Tactics including compulsory licensing, tax incentives, and substitution to support the use of domestic generics should ring alarm bells for multinationals, observers say.
